Clinical trials: Cognition - Other
Schizophrenia, Cognition
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of…
- Conditions
- Schizophrenia, Cognition, Psychosis
- Trial name
- NCT02104752
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Schizophrenia
Effects of Galantamine on Cognition
Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early twenties, with cognitive impairments and negative symptoms frequently emerging much earlier.
- Trial name
- NCT01100775
- Testing
- Galantamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Memory Disorders
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit…
- Conditions
- Schizophrenia, Memory Disorders, Cognition Disorders
- Trial name
- Atomoxetine (NCT00548327)
- Testing
- Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.
- Trial name
- NCT00176423
- Testing
- galantamine
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Maryland, Baltimore
Parkinson Disease
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
The major purpose of this study is to assess the efficacy of CBD on motor symptoms of Parkinson's Disease (PD), and secondarily to study the safety and tolerability of CBD and other efficacy, particularly regarding tremor in PD.
- Trial name
- NCT03582137
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Colorado, Denver
Schizophrenia, Schizoaffective Disorder
Antipsychotic Effects on Brain Function in Schizophrenia
The purpose of the study is to determine whether two commonly-prescribed antipsychotic medications (aripiprazole and risperidone) have different effects on brain function and cognition in schizophrenia patients.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- APD (NCT01913327)
- Testing
- Aripiprazole, Risperidone, Modafinil
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Francisco
Schizophrenia
A Multicenter Study of NAP (AL-108) in Schizophrenia
The TURNS is a NIMH-funded contract for the evaluation of new compounds for the treatment of cognitive impairments in schizophrenia (HHSN 27820044 1003C; P.I.: Steve Marder, M.D.).
- Trial name
- AL-108 (NCT00505765)
- Testing
- AL-108
- Where
- 8 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of California, Los Angeles
Schizophrenia
A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia.
- Trial name
- NAC (NCT01232790)
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
The study looks at whether treatment with iloperidone (Fanapt) is associated with improvements in social cognition in individuals who have been recently diagnosed with schizophrenia or schizoaffective disorder.
- Trial name
- NCT01929889
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Psychosis
USS Training to Improve Social Function in People With Psychosis
Psychotic spectrum disorders (PSD) are associated with poor social function. By doing this study, the investigators hope to learn which of two different types of 2-month long training courses is more effective in improving…
- Trial name
- NCT04557124
- Testing
- USS, MovingForward
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
The objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic…
- Trial name
- NCT02832037
- Testing
- BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3
- Where
- 81 sites in United States, Austria and 9 more
- Volunteers
- 509 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Different Safety Profile of Risperidone and Paliperidone Extended-release
The main objective of this study was to assess subjective experiences related to secondary negative symptoms and cognitive performance in healthy volunteers in response to multiple doses of paliperidone ER and risperidone in a…
- Trial name
- NCT01284959
- Testing
- risperidone, paliperidone ER
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Schizophrenia, Schizoaffective Disorder
Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.
- Trial name
- NCT01658150
- Testing
- isradipine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia
Modafinil Effects on Cognition in Schizophrenia Patients
Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This includes many types of cognitive dysfunction, such as in attention, memory and language.
- Trial name
- InO (NCT00711464)
- Testing
- modafinil (M1, M2, M4)
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Alzheimer Disease, Dementia
Movement Intervention for Memory Enhancement
Dancing is a complex sensorimotor rhythmic activity that integrates cognitive, physical, and social components and is applicable to seniors with various fitness levels.
- Conditions
- Alzheimer Disease, Dementia, Cognitive Decline, Cognitive Impairment
- Trial name
- MIME (NCT03475316)
- Testing
- Social Dancing, Treadmill Walking
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Schizophrenia
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
The primary aim of the study is to determine the efficacy of adjunctive valacyclovir, in comparison to placebo, to improve visual (Brief Visuospatial Memory Test) and working (composite score of the Spatial Span and Letter Number…
- Trial name
- VISTA (NCT02008773)
- Testing
- Valacyclovir HCI 500 mg tablets
- Where
- 13 sites in United States
- Volunteers
- 170 people
- Sponsor
- Indiana University
Schizophrenia, Insomnia Related to Schizophrenia (307.42)
Sodium Oxybate in Schizophrenia With Insomnia
The present protocol proposes study of the recently approved compound sodium oxybate (Xyrem), a gamma-aminobutyric acid type b (GABAB) and a g-hydroxybutyric acid (GHB) receptor agonist, for the study of persistent symptoms of…
- Trial name
- NCT00594256
- Testing
- Sodium Oxybate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Cognition - Other
Cognition Intervention Study Dortmund
Major aim of this study is to add scientifically proven insights into cognitive effects of meals to the existing recommendations for school meals in Germany.
- Trial name
- CogniDO (NCT01401153)
- Testing
- Skipping lunch
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Research Institute of Child Nutrition, Dortmund
Schizophrenia, Schizoaffective Disorder
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months.
- Trial name
- NCT00373672
- Testing
- armodafinil (Nuvigil)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Northwestern University
Schizophrenia
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04846868
- Testing
- Iclepertin
- Where
- 116 sites in United States, Australia and 15 more
- Volunteers
- 620 people
- Sponsor
- Boehringer Ingelheim